Hepatitis (B,C,HIV) – ICT at Dr. Essa Lab

Hepatitis (B,C,HIV) – ICT at Dr. Essa Lab

The Hepatitis (B,C,HIV) – ICT at Dr. Essa Lab is a highly advanced, rapid screening panel designed to identify the presence of three of the most clinically significant blood-borne viral pathogens: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human Immunodeficiency Virus (HIV types 1 and 2). Utilizing the Immunochromatographic Test (ICT) method, also referred to as a lateral flow immunoassay, this diagnostic panel delivers qualitative results with exceptional speed and efficiency. Dr. Essa Laboratory & Diagnostic Centre, an established leader in diagnostic pathology in Pakistan, performs this screening under rigorous quality control standards to ensure clinical reliability for patients, healthcare professionals, and administrative authorities alike.

The biochemical mechanism of the immunochromatographic test is based on the principles of antigen-antibody specificity and capillary migration. The test cassette contains a membrane strip pre-coated with specific capture reagents at designated test regions. When a patient’s serum, plasma, or whole blood specimen is applied to the sample well, it migrates chromatographically along the membrane via capillary action. If the sample contains the target analytes—specifically, Hepatitis B Surface Antigen (HBsAg), antibodies directed against the Hepatitis C Virus (anti-HCV), or antibodies against HIV-1 and HIV-2 (anti-HIV 1/2)—they bind to colloidal gold-conjugated antibodies or antigens present in the conjugate pad. This antigen-antibody complex continues to migrate until it is captured by the immobilized reagents on the membrane, producing a visible colored band in the respective test window. A control band (C-line) must always appear in each channel to confirm that the liquid has migrated correctly and that the test reagents are fully functional, validating the diagnostic run.

The clinical value of screening for HBV, HCV, and HIV concurrently is immense, given their overlapping transmission routes and the potential for co-infection. These viruses are primarily transmitted through exposure to infected blood, contaminated needles, sexual contact, and vertical transmission from mother to child during childbirth. Because the early stages of these infections are frequently asymptomatic, individuals can carry and transmit these pathogens for years without exhibiting clinical symptoms. If left undiagnosed and untreated, chronic Hepatitis B and C can lead to severe hepatic complications, including progressive liver fibrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma. Similarly, undetected HIV infection progressively depletes CD4+ T-lymphocytes, compromising the host immune system and eventually leading to Acquired Immunodeficiency Syndrome (AIDS). Rapid screening via the Hepatitis (B,C,HIV) – ICT panel at Dr. Essa Lab serves as a vital first-line diagnostic tool, enabling early clinical intervention, preventing community transmission, and guiding subsequent confirmatory testing pathways such as Enzyme-Linked Immunosorbent Assay (ELISA) or quantitative Polymerase Chain Reaction (PCR) molecular assays.

Clinical Procedure: What to Expect

Patient Preparation

• No Fasting Required: Patients do not need to fast before undergoing the Hepatitis (B,C,HIV) – ICT blood test; dietary intake does not affect the immunochromatographic detection of viral antigens or antibodies.
• Medication Disclosure: It is essential to inform the healthcare provider or laboratory staff of any ongoing medications, particularly immunosuppressants, corticosteroids, or antiretroviral therapies, as these can potentially modulate the immune response and affect antibody production.
• Identification Documents: Patients should bring valid identification, such as a Computerized National Identity Card (CNIC) or passport, especially if the test is required for official visa medical examinations, pre-employment clearance, or immigration purposes.
• Hydration: Maintaining adequate hydration by drinking plenty of water prior to the blood draw is highly recommended, as it expands blood volume and makes the veins in the arm more prominent and easier to access.
• Comfortable Attire: Wear loose-fitting clothing with sleeves that can be easily rolled up above the elbow to facilitate unobstructed access to the venipuncture site.

During the Procedure

The venipuncture procedure is conducted by a trained phlebotomist in a sterile, comfortable clinical environment. The patient is asked to sit comfortably, and their identity is verified against the test requisition form. The phlebotomist then inspects the antecubital fossa of the arm to select a suitable vein, typically the median cubital vein, which offers the best access and stability. A sterile tourniquet is applied a few inches above the selected site to transiently restrict venous return, causing the vein to engorge and become palpable.

The skin over the selected vein is thoroughly cleansed with an antiseptic swab containing 70% isopropyl alcohol, using a circular motion from the center outward, and allowed to air dry completely. This step is critical to prevent contamination of the sample and protect the patient from infection. Using a sterile, single-use needle attached to a vacuum collection tube (typically a red-top or gold-top serum separator tube), the phlebotomist gently punctures the vein. Once the required volume of blood is collected, the tourniquet is released, the needle is smoothly withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad to promote hemostasis. An adhesive bandage is applied, and the patient is advised to keep it on for at least 15 minutes. The collected blood sample is then centrifuged to separate the serum or plasma, which is immediately applied to the ICT test cassette for rapid analysis.

When is a Hepatitis (B,C,HIV) – ICT Performed?

Pre-Employment and Visa Medical Screenings

Many corporate organizations, government agencies, and international visa authorities—particularly those representing Gulf Cooperation Council (GCC) countries—mandate comprehensive infectious disease screenings for prospective employees and travelers. The Hepatitis (B,C,HIV) – ICT panel is widely utilized for this purpose due to its rapid turnaround time and high screening sensitivity. It ensures that individuals entering specific workforces, particularly healthcare, food handling, and hospitality, do not pose a public health risk and are aware of their health status before relocation or employment.

Pre-Operative and Pre-Surgical Evaluations

Prior to undergoing any surgical or invasive medical procedure, patients are routinely screened for blood-borne pathogens. This screening is vital for several reasons: it allows the surgical team to implement enhanced biosafety precautions to prevent occupational exposure and needle-stick injuries, guides post-operative patient care, and ensures that surgical instruments undergo specialized sterilization protocols. Identifying a patient’s positive status beforehand also helps anesthesiologists and surgeons monitor liver function and immune status during the perioperative period.

High-Risk Exposure and Needle-Stick Injuries

Healthcare professionals, emergency responders, and individuals who experience accidental needle-stick injuries, mucosal exposure to body fluids, or unprotected sexual contact require immediate screening. The Hepatitis (B,C,HIV) – ICT test is performed as an emergency baseline evaluation. While the test may not detect an infection acquired hours prior due to the window period, establishing baseline negativity is crucial for medical-legal documentation and for initiating Post-Exposure Prophylaxis (PEP) for HIV or Hepatitis B immunizations.

Blood and Organ Donation Screening

To maintain the safety of the blood supply and prevent transfusion-transmitted infections (TTIs), all potential blood and organ donors must undergo rigorous screening. The rapid nature of the ICT panel makes it an excellent initial screening tool at blood donation camps and transplant centers. Any donor unit that tests reactive for HBsAg, anti-HCV, or anti-HIV is immediately discarded, and the donor is confidentially notified and referred for confirmatory molecular testing.

Antenatal and Prenatal Care

Obstetricians routinely order screening for Hepatitis B, Hepatitis C, and HIV during early pregnancy. Vertical transmission from an infected mother to her fetus or newborn during gestation, labor, or delivery is a primary route of infection. Detecting these pathogens early allows for timely clinical interventions, such as administering Hepatitis B immunoglobulin (HBIG) and the HBV vaccine to the newborn within hours of birth, or initiating antiretroviral therapy (ART) in HIV-positive pregnant women, which dramatically reduces the risk of transmission to the child.

What Does a Hepatitis (B,C,HIV) – ICT Detect?

The Hepatitis (B,C,HIV) – ICT panel is designed to detect specific immunological markers associated with active, chronic, or past infections. Here is a detailed breakdown of what the test evaluates and detects:

• Hepatitis B Surface Antigen (HBsAg): Detects the outer protein coat of the Hepatitis B virus, which is the earliest indicator of an active HBV infection.
• Acute HBV Infection: Identifies the presence of HBsAg during the early, acute phase of Hepatitis B, often before symptoms appear.
• Chronic HBV Carrier Status: Detects persistent HBsAg in the blood for more than six months, indicating chronic Hepatitis B infection.
• Hepatitis C Antibodies (Anti-HCV): Detects the presence of specific antibodies produced by the body’s immune system in response to HCV proteins.
• Active HCV Infection: Indicates a potential active replication of the Hepatitis C virus, requiring confirmation via HCV RNA PCR.
• Past Resolved HCV Infection: Can detect antibodies that remain in the blood even after a patient has successfully cleared the virus naturally or through antiviral therapy.
• HIV-1 Antibodies: Detects specific antibodies directed against Human Immunodeficiency Virus Type 1, the most common strain globally.
• HIV-2 Antibodies: Detects antibodies against Human Immunodeficiency Virus Type 2, which is primarily endemic to West Africa but found worldwide.
• Early Seroconversion: Identifies the development of detectable antibody levels against HIV, typically appearing within 3 to 12 weeks post-exposure.
• Control Line (C-Line) Validity: Confirms that the liquid sample has migrated successfully across the chromatographic membrane and that the test kit is functional.
• Test Line (T-Line) Reactivity: Visually demonstrates the binding of target antigens or antibodies to the immobilized capture reagents on the strip.
• Qualitative Presence: Provides a clear